TABLE 5

Phenotypic analysis and prevalence of signature NS5A resistance-conferring amino acid variants relative to baseline by clonal sequencing

Dose QD (mg) and patientVisit dayEC50 (pM)Fold resistanceaTreatment-emergent variants at signature resistance-conferring amino acid positions in NS5A (% frequency)b
Multiple variantsM28Q30Y93
TVERCHNS
5
    1319.441100
646.298263130
    231.72.7218
62.33.7156
25
    3312.21816243715
624.536165214
50
    4375.81054622516
62543534913255
    5318021962c1022
633340644c1139
200
    661,4772,23865228
    7310319818211719
6482927403566
    839632,00634555
68921,85840505
  • a Fold change in EC50 of ombitasvir in samples from day 3 or day 6 relative to the EC50 in the respective baseline sample.

  • b Variants observed in ≥5% of the clones are shown.

  • c Q30L + Y93H was the major double variant, and Q30L + Y93S was the minor variant.